Eberlein U, Lassmann M
University Wuerzburg, Department of Nuclear Medicine, Oberdürrbacher Str. 6, D-97080 Würzburg, Germany.
Appl Radiat Isot. 2013 Jun;76:70-4. doi: 10.1016/j.apradiso.2012.06.033. Epub 2012 Jul 20.
This review compiles and analyzes the available dosimetry data of [(68)Ga] labeled compounds. Dosimetry data are given for [(68)Ga]DOTA-NOC, TOC, TATE, and NODAGA-RGDyK. The number of PET-scans with [(68)Ga]DOTA-compounds for imaging neuroendocrine tumors is increasing because [(68)Ga] has a higher affinity to somatostatin receptors (SSTR) in comparison to comparable [(111)In]-compounds. In addition, the better image resolution of the PET images provides improved diagnostics. Despite its widespread use literature on dosimetry of [(68)Ga]-labeled radiopharmaceuticals is sparse. In some cases the description of the underlying methodology is missing or human data are gained from the extrapolation of animal experiments. More and better documented dosimetry data will further promote the use of these promising new agents.
本综述汇编并分析了[(68)Ga]标记化合物的现有剂量学数据。给出了[(68)Ga]DOTA-NOC、TOC、TATE和NODAGA-RGDyK的剂量学数据。用于神经内分泌肿瘤成像的[(68)Ga]DOTA化合物的PET扫描数量正在增加,因为与类似的[(111)In]化合物相比,[(68)Ga]对生长抑素受体(SSTR)具有更高的亲和力。此外,PET图像更好的图像分辨率提供了改进的诊断效果。尽管[(68)Ga]标记的放射性药物广泛使用,但其剂量学方面的文献却很稀少。在某些情况下,缺少对基础方法的描述,或者人体数据是从动物实验的外推中获得的。更多且记录更完善的剂量学数据将进一步推动这些有前景的新药物的使用。